BR112022000760A2 - Composições, método para preparar um conjugado de longa duração de um polipeptídeo fisiologicamente ativo e conjugado de fármaco de longa duração - Google Patents

Composições, método para preparar um conjugado de longa duração de um polipeptídeo fisiologicamente ativo e conjugado de fármaco de longa duração

Info

Publication number
BR112022000760A2
BR112022000760A2 BR112022000760A BR112022000760A BR112022000760A2 BR 112022000760 A2 BR112022000760 A2 BR 112022000760A2 BR 112022000760 A BR112022000760 A BR 112022000760A BR 112022000760 A BR112022000760 A BR 112022000760A BR 112022000760 A2 BR112022000760 A2 BR 112022000760A2
Authority
BR
Brazil
Prior art keywords
long
acting
conjugate
preparing
compositions
Prior art date
Application number
BR112022000760A
Other languages
English (en)
Other versions
BR112022000760B1 (pt
Inventor
Cheongbyeol Shin
Hyun Kim Dong
Dooseo Jang
Eun Lee Ji
Hye Moon Ji
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of BR112022000760A2 publication Critical patent/BR112022000760A2/pt
Publication of BR112022000760B1 publication Critical patent/BR112022000760B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/321—Polymers modified by chemical after-treatment with inorganic compounds
    • C08G65/325—Polymers modified by chemical after-treatment with inorganic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

composições, método para preparar um conjugado de longa duração de um polipeptídeo fisiologicamente ativo e conjugado de fármaco de longa duração. a presente invenção se refere a um método inédito para preparar um conjugado de fármaco de longa duração e um conjugado de fármaco de longa duração preparado usando o método.
BR112022000760-4A 2019-07-18 2019-07-18 Composições, método para preparar um conjugado de longa duração de um polipeptídeo fisiologicamente ativo e conjugado de fármaco de longa duração BR112022000760B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2019/008912 WO2021010532A1 (ko) 2019-07-18 2019-07-18 신규 중간체 제조를 통한 지속형 약물 결합체의 제조 방법

Publications (2)

Publication Number Publication Date
BR112022000760A2 true BR112022000760A2 (pt) 2022-03-15
BR112022000760B1 BR112022000760B1 (pt) 2024-01-02

Family

ID=74210441

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000760-4A BR112022000760B1 (pt) 2019-07-18 2019-07-18 Composições, método para preparar um conjugado de longa duração de um polipeptídeo fisiologicamente ativo e conjugado de fármaco de longa duração

Country Status (12)

Country Link
US (2) US11717577B2 (pt)
EP (1) EP4001303A4 (pt)
JP (2) JP7394207B2 (pt)
KR (2) KR102478588B1 (pt)
CN (1) CN114945587A (pt)
AU (1) AU2019457235C1 (pt)
BR (1) BR112022000760B1 (pt)
CA (1) CA3147883C (pt)
MX (1) MX2022000758A (pt)
NZ (1) NZ784956A (pt)
PE (1) PE20220393A1 (pt)
WO (1) WO2021010532A1 (pt)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
MY149128A (en) 2005-08-16 2013-07-15 Hanmi Science Co Ltd A method for the mass production of immunoglobulin fc region deleted initial methionine residues
BRPI0710011A2 (pt) 2006-04-14 2011-08-02 Trubion Pharmaceuticals Inc proteìnas de ligação compreendendo articulação de imunoglobulina e regiões fc dotadas de funções efetoras fc alteradas
CA2688275A1 (en) 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
US9950564B2 (en) * 2010-04-05 2018-04-24 Douglas G. Willis Articulating carriage
CA2792942A1 (en) * 2010-04-09 2011-10-13 Merck Sharp & Dohme Corp. Novel single chemical entities and methods for delivery of oligonucleotides
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
GB201203071D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
KR102073748B1 (ko) * 2013-01-31 2020-02-05 한미약품 주식회사 재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법
RU2677796C9 (ru) 2013-03-05 2019-03-15 Ханми Фарм. Ко., Лтд. Улучшенный способ получения конъюгата физиологически активного полипептида с высоким выходом
JP6602746B2 (ja) * 2013-03-15 2019-11-06 カポン、ダニエル・ジェイ． 非ペプチジル結合を含むハイブリッド免疫グロブリン
KR101895634B1 (ko) * 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
EP3341025A4 (en) 2015-09-24 2019-05-01 Hanmi Pharm. Co., Ltd. PROTEIN COMPLEX BY USING A SPECIFIC ROLE OF AN IMMUNOMOBILIN FRAGMENT FOR LINKING
KR102247701B1 (ko) * 2016-02-26 2021-05-03 한미정밀화학주식회사 폴리에틸렌글리콜 디알데히드 유도체의 제조방법
JP6937773B2 (ja) * 2016-03-07 2021-09-22 ハンミ ファーマシューティカル カンパニー リミテッド ポリエチレングリコール誘導体及びその用途
JP7121024B2 (ja) * 2017-02-07 2022-08-17 ハンミ ファーマシューティカルズ カンパニー リミテッド 非ペプチド性重合体リンカー化合物、そのリンカー化合物を含む結合体、及びそれらの製造方法
CN111164128A (zh) * 2017-09-29 2020-05-15 韩美药品株式会社 包含作为接头的非肽基聚合物偶联的脂肪酸衍生物化合物的蛋白复合物及其制备方法

Also Published As

Publication number Publication date
EP4001303A4 (en) 2023-05-31
US20230248843A1 (en) 2023-08-10
JP7394207B2 (ja) 2023-12-07
AU2019457235B2 (en) 2022-06-16
JP2022532445A (ja) 2022-07-14
CN114945587A (zh) 2022-08-26
PE20220393A1 (es) 2022-03-18
US20230103271A2 (en) 2023-03-30
AU2019457235C1 (en) 2022-12-22
KR20210010428A (ko) 2021-01-27
AU2019457235A1 (en) 2022-03-03
US11717577B2 (en) 2023-08-08
KR102478588B1 (ko) 2022-12-16
WO2021010532A1 (ko) 2021-01-21
JP2023182575A (ja) 2023-12-26
KR20220022899A (ko) 2022-02-28
NZ784956A (en) 2023-01-27
US20220257788A1 (en) 2022-08-18
MX2022000758A (es) 2022-02-11
CA3147883C (en) 2024-01-02
CA3147883A1 (en) 2021-01-21
KR102334315B1 (ko) 2021-12-06
BR112022000760B1 (pt) 2024-01-02
EP4001303A1 (en) 2022-05-25

Similar Documents

Publication Publication Date Title
BR112018002499A2 (pt) método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica
MX2021010314A (es) Derivados de tiazol como inhibidores de la secreción de proteínas.
MX2021006969A (es) Ligante peptidico.
BRPI1016132B8 (pt) composição, formulação farmacêutica, processo de obtenção de uma formulação farmacêutica estável
MX2018003096A (es) Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma.
MY195550A (en) Antibody Formulation
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
EA202192405A1 (ru) Составы антител против il-36r
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CL2021003273A1 (es) Composición farmacéutica parenteral del agonista dual glp1/2
WO2018097603A3 (ko) 중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법
MX2019012454A (es) Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.
MX2022006519A (es) Medicamento conjugado con polietilenglicol, metodo de preparacion del mismo y uso del mismo.
BR112017001093A2 (pt) formulação aquosa compreendendo paracetamol e ibuprofeno
BR112022002623A2 (pt) Composição, composição compreendendo praziquantel, emodepsida e um componente solvente, método para produzir uma composição e composição para uso
EA202090319A1 (ru) Пептидные конъюгаты, способ конъюгации и их использование
MX2023002117A (es) Forma amorfa de un inhibidor de malt1 y formulaciones de este.
BR112022000760A2 (pt) Composições, método para preparar um conjugado de longa duração de um polipeptídeo fisiologicamente ativo e conjugado de fármaco de longa duração
MX2022000287A (es) Composición de inhibidor micromolécular de pi4kiiia, método de preparación y uso.
EP4053151A4 (en) KERATIN BD-1, PREPARATION METHOD, AS WELL AS PHARMACEUTICAL COMPOSITION AND USE THEREOF
MX2022004209A (es) Formas cristalinas de estado solido de un modulador selectivo de canales de potasio.
WO2020127819A3 (en) Pharmaceutical composition comprising apixaban
EA202190328A1 (ru) Фармацевтическая композиция, содержащая тикагрелор
WO2023235660A3 (en) Flavivirus immunogens and vaccine compositions and methods of using the same
BR112021002126A2 (pt) Composição para dispensação de vírus, e, método para preparação de uma composição para dispensação de vírus.

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/07/2019, OBSERVADAS AS CONDICOES LEGAIS